In vitro functional analysis of 24 novel CYP2C19 variants recently found in the Chinese Han population

References

• Bozina N, Granic P, Lalic Z, et al. (2003). Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 44:425–8
   PubMed Web of Science ®Google Scholar
• Chang M, Tybring G, Dahl ML, et al. (1995). Interphenotype differences in disposition and effect on gastrin levels of omeprazole–suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39:511–18
   PubMed Web of Science ®Google Scholar
• Chen L, Qin S, Xie J, et al. (2008). Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9:691–702
   PubMed Web of Science ®Google Scholar
• Chiba K, Shimizu K, Kato M, et al. (2014). Prediction of inter-individual variability in pharmacokinetics of CYP2C19 substrates in humans. Drug Metab Pharmacokinet 29:379–86
   PubMed Web of Science ®Google Scholar
• Dai DP, Wang YH, Wang SH, et al. (2013). In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population. Acta Pharmacol Sin 34:1449–56
   PubMed Web of Science ®Google Scholar
• Dai DP, Wang SH, Geng PW, et al. (2014a). In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride. Basic Clin Pharmacol Toxicol 114:305–10
   PubMed Web of Science ®Google Scholar
• Dai DP, Xu RA, Hu LM, et al. (2014b). CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J 14:85–92
   PubMed Web of Science ®Google Scholar
• Dai DP, Geng PW, Cai J, et al. (2015a). 293FT is a highly suitable mammalian cell line for the in vitro enzymatic activity analysis of typical P450 proteins. Pharmazie 70:33–7
   PubMed Web of Science ®Google Scholar
• Dai DP, Geng PW, Wang SH, et al. (2015b). In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population. Basic Clin Pharmacol Toxicol 117:39--43
   Google Scholar
• De Morais SM, Wilkinson GR, Blaisdell J, et al. (1994). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–8
   PubMed Web of Science ®Google Scholar
• Garcia-Barcelo M, Chow LY, Kum Chiu HF, et al. (1999). Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Clin Chem 45:2273–4
   PubMed Web of Science ®Google Scholar
• Hanioka N, Tsuneto Y, Saito Y, et al. (2007). Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. Xenobiotica 37:342–55
   PubMed Web of Science ®Google Scholar
• Hiratsuka M. (2012). In vitro assessment of the allelic variants of cytochrome P450. Drug Metabol Pharmacokinet 27:68–84
   PubMed Web of Science ®Google Scholar
• Hou X, Shi J, Sun H. (2014). Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol 70:1041–7
   PubMed Web of Science ®Google Scholar
• Hu LM, Dai DP, Hu GX, et al. (2012). Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population. Pharmacogenomics 13:1571–81
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ, et al. (2008). The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236–42
   PubMed Web of Science ®Google Scholar
• Lee IS, Kim D. (2011). Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch Pharm Res 34:1799–816
   PubMed Web of Science ®Google Scholar
• Lee MY, Borgiani P, Johansson I, et al. (2014). High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Pharmacogenomics J 14:343–9
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim WY, Kim H, et al. (2009). Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos 37:2262–9
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Bertilsson L, Johansson I, et al. (1995). Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57:656–61
   PubMed Web of Science ®Google Scholar
• Niinuma Y, Saito T, Takahashi M, et al. (2014). Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 14:107–14
   PubMed Web of Science ®Google Scholar
• Ono S, Hatanaka T, Miyazawa S, et al. (1996). Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 26:1155–66
   PubMed Web of Science ®Google Scholar
• Orengo-Mercado C, Nieves B, Lopez L, et al. (2013). Frequencies of functional polymorphisms in three pharmacokinetic genes of clinical interest within the admixed puerto rican population. J Pharmacogenom Pharmacoproteom 4:1000113
   Google Scholar
• Owusu Obeng A, Egelund EF, Alsultan A, et al. (2014). CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy 34:703–18
   PubMed Web of Science ®Google Scholar
• Reynald RL, Sansen S, Stout CD, et al. (2012). Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19. J Biol Chem 287:44581–91
   PubMed Web of Science ®Google Scholar
• Shu Y, Zhou HH. (2000). Individual and ethnic differences in CYP2C19 activity in Chinese populations. Acta Pharmacol Sin 21:193–9
   PubMed Web of Science ®Google Scholar
• Strom CM, Goos D, Crossley B, et al. (2012). Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med 14:95–100
   PubMed Web of Science ®Google Scholar
• Takahashi M, Saito T, Ito M, et al. (2015). Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. Pharmacogenomics J 15:26–32
   PubMed Web of Science ®Google Scholar
• Uno T, Sugimoto K, Sugawara K, et al. (2008). The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 30:276–81
   PubMed Web of Science ®Google Scholar
• Wang YH, Pan PP, Dai DP, et al. (2014). Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. Xenobiotica 44:270–5
   PubMed Web of Science ®Google Scholar
• Wester MR, Lasker JM, Johnson EF, et al. (2000). CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos 28:354–9
   PubMed Web of Science ®Google Scholar
• Yan F, Xu JF, Liu XF, et al. (2014). Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population. Tumour Biol 35:5295–8
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295
   PubMed Web of Science ®Google Scholar